Pharmaceutical

STAT+: FDA’s Janet Woodcock to retire early next year

STAT+: FDA’s Janet Woodcock to retire early next year

Nov 17, 2023

Principal Deputy FDA Commissioner Janet Woodcock will retire early next year fro...

Key questions (and answers) about the historic approval of a CRISPR-based medicine

Key questions (and answers) about the historic approval...

Nov 17, 2023

Here are some key questions (and answers) about the historic approval of a CRISP...

Listen: A CRISPR milestone, algorithms amok, & biotech ...

Nov 17, 2023

This week on "The Readout LOUD" podcast: A CRISPR milestone, algorithms amok, an...

Colon cancer screening kits have a high rate of untestable samples

Colon cancer screening kits have a high rate of untesta...

Nov 17, 2023

More than 10% of the tests used for routine colorectal cancer screening containe...

Report: Measles cases and deaths increase worldwide, as childhood vaccinations rates decline

Report: Measles cases and deaths increase worldwide, as...

Nov 17, 2023

A dangerous decline in the rate of children vaccinated against measles is spurri...

STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant

STAT+: FDA cites Dr. Reddy’s for quality control proble...

Nov 17, 2023

Dr. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cit...

Progress in childhood cancer has stalled for Blacks and Hispanics, report says

Progress in childhood cancer has stalled for Blacks and...

Nov 17, 2023

The overall cancer death rate for children and teenagers in the U.S. in 2021 was...

STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data

STAT+: Pharmalittle: U.K. approves world’s first CRISPR...

Nov 17, 2023

U.K. regulators approved a CRISPR-based medicine to treat sickle cell disease an...

How do we know Alzheimer’s drugs ‘work’?

How do we know Alzheimer’s drugs ‘work’?

Nov 17, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation

STAT+: Bristol wins U.S. approval for lung cancer drug ...

Nov 17, 2023

The Food and Drug Administration on Wednesday approved a new treatment for peopl...

Plocabulin by Pharma Mar for Biliary Tumor: Likelihood ...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Adenocarcinoma: Likelihood...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Peritoneal Cancer: Likelih...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Epithelial Ovarian Cancer:...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Pembrolizumab by Merck for Sezary Syndrome: Likelihood ...

Nov 16, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase II f...

Pembrolizumab by Merck for Mycosis Fungoides: Likelihoo...

Nov 16, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase II f...